Guiyang Xintian Pharmaceutical Co Ltd Market Cap ($266.11 Million)
Market Cap & Net Worth: Guiyang Xintian Pharmaceutical Co Ltd (002873)
Guiyang Xintian Pharmaceutical Co Ltd market cap. Guiyang Xintian Pharmaceutical Co Ltd (SHE:002873) has a market capitalization of $266.11 Million (CN¥1.82 Billion) as of November 4, 2026. Listed on the SHE stock exchange, this China-based company holds position #15110 globally and #4437 in its home market, demonstrating a -4.97% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Guiyang Xintian Pharmaceutical Co Ltd's stock price CN¥7.45 by its total outstanding shares 244103806 (244.10 Million). Also see 002873 cash flow conversion for how efficiently the company converts equity into cash flow.
Guiyang Xintian Pharmaceutical Co Ltd Market Cap History (2017–2026)
Guiyang Xintian Pharmaceutical Co Ltd market cap history from 2017 to 2026. Data shows change from $436.01 Million to $266.11 Million (-0.25% CAGR). Check latest Guiyang Xintian Pharmaceutical Co Ltd stock price today for real-time trading data and today's change.
Guiyang Xintian Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Guiyang Xintian Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Guiyang Xintian Pharmaceutical Co Ltd (002873) equity growth momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.47x
Guiyang Xintian Pharmaceutical Co Ltd's market cap is 0.47 times its annual revenue
Latest Price to Earnings (P/E) Ratio
38.89x
Guiyang Xintian Pharmaceutical Co Ltd's market cap is 38.89 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $436.01 Million | $681.71 Million | $66.12 Million | 0.64x | 6.59x |
| 2018 | $285.18 Million | $694.26 Million | $70.98 Million | 0.41x | 4.02x |
| 2019 | $297.01 Million | $773.34 Million | $71.42 Million | 0.38x | 4.16x |
| 2020 | $287.87 Million | $750.95 Million | $74.10 Million | 0.38x | 3.88x |
| 2021 | $504.10 Million | $969.84 Million | $100.61 Million | 0.52x | 5.01x |
| 2022 | $509.43 Million | $1.09 Billion | $111.52 Million | 0.47x | 4.57x |
| 2023 | $441.29 Million | $953.98 Million | $80.87 Million | 0.46x | 5.46x |
| 2024 | $338.27 Million | $857.55 Million | $52.32 Million | 0.39x | 6.47x |
| 2025 | $354.34 Million | $749.72 Million | $9.11 Million | 0.47x | 38.89x |
Competitor Companies of 002873 by Market Capitalization
Companies near Guiyang Xintian Pharmaceutical Co Ltd in the global market cap rankings as of November 4, 2026. Also see 002873 asset base for a full breakdown of the balance sheet.
Key companies related to Guiyang Xintian Pharmaceutical Co Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Guiyang Xintian Pharmaceutical Co Ltd (2017–2026)
Market capitalization of Guiyang Xintian Pharmaceutical Co Ltd from 2017 to today. Between 2017 and today, Guiyang Xintian Pharmaceutical Co Ltd's market cap moved from $436.01 Million to $ 266.11 Million, with a yearly change of -0.25%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥266.11 Million | -24.90% |
| 2025 | CN¥354.34 Million | +4.75% |
| 2024 | CN¥338.27 Million | -23.34% |
| 2023 | CN¥441.29 Million | -13.38% |
| 2022 | CN¥509.43 Million | +1.06% |
| 2021 | CN¥504.10 Million | +75.11% |
| 2020 | CN¥287.87 Million | -3.08% |
| 2019 | CN¥297.01 Million | +4.15% |
| 2018 | CN¥285.18 Million | -34.59% |
| 2017 | CN¥436.01 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Guiyang Xintian Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $266.11 Million USD |
| MoneyControl | $266.11 Million USD |
| MarketWatch | $266.11 Million USD |
| marketcap.company | $266.11 Million USD |
| Reuters | $266.11 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Guiyang Xintian Pharmaceutical Co Ltd
Guiyang Xintian Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the research, development, production, and sale of new traditional Chinese medicines in China. The company offers products in various dosage forms, including hard capsules, oral solutions, granules, gels, tablets, syrups, tinctures, lotions, medicated wines, and elixirs. Its products are used for the treatment of … Read more